文献速递腹部MR

匹配MR场强后LI-RADS v2018鉴别HCC与肝内CCA及混合型HCC-CCA

Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
PubMed 文献 · Abdom Radiol (NY) · 2021-03-03

回顾性纳入病理证实的198例204个病灶(102个HCC、78个iCCA、24个cHCC-CCA),HCC按年龄、肿瘤大小、MR扫描仪和肿瘤数目与iCCA或cHCC-CCA匹配。双读者按LI-RADS v2018独立评估,LR-5或LR-TIV诊断HCC的敏感度68.63%、特异度85.29%;LR-M或LR-TIV诊断非HCC恶性肿瘤的敏感度72.55%、特异度86.27%。3T MR诊断HCC的敏感度高于1.5T(80.00% vs 57.69%,P=0.015)。

要点

  • LR-5/LR-TIV诊断HCC特异度85.29%,敏感度68.63%,敏感度欠佳。
  • LR-M/LR-TIV对iCCA敏感度82.05%,对cHCC-CCA仅41.67%。
  • 近半数cHCC-CCA(45.83%,11/24)被归为LR-5,需警惕误判。

诊断标准与关键数值

  • LR-5或LR-TIV(肯定HCC)诊断HCC的敏感度68.63%、特异度85.29%。
  • LR-M或LR-TIV(可能非HCC恶性肿瘤)诊断非HCC恶性肿瘤的敏感度72.55%、特异度86.27%。
  • LR-M或LR-TIV对iCCA的敏感度82.05%,对cHCC-CCA的敏感度41.67%。
  • 45.83%(11/24)的cHCC-CCA被归为LR-5。
  • 3T MR诊断HCC敏感度80.00% vs 1.5T 57.69%(P=0.015)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To eliminate the effects of field strength in determining the diagnostic performance of the LI-RADS version 2018 (LI-RADS v2018) in differentiating hepatocellular carcinoma (HCC) from non-HCC primary liver malignancy in high-risk patients.

METHODS: Patients who were pathologically confirmed intrahepatic cholangiocarcinoma (iCCA) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA) were retrospectively reviewed. Patients with HCC were matched to the iCCA or cHCC-CCA patients on age, tumor size, MR scanner, and number of tumors. Two readers independently evaluated the lesions according to LI-RADS v2018. Diagnostic performance of LI-RADS v2018 in differentiating HCC from non-HCC primary liver malignancy were analyzed.

RESULTS: A total of 198 patients with 204 lesions (102 HCCs, 78 iCCAs, and 24 cHCC-CCAs) were enrolled. The sensitivity and specificity of LR-5 or LR-TIV (definitely due to HCC) in diagnosing HCC were 68.63% and 85.29%, respectively. LR-M or LR-TIV (may be due to non-HCC malignancy) had a sensitivity of 72.55% and a specificity of 86.27% in diagnosing non-HCC malignancy. The sensitivity of LR-M or LR-TIV (may be due to non-HCC malignancy) for iCCA and cHCC-CCA was 82.05% and 41.67%, respectively. Nearly half (11/24, 45.83%) of cHCC-CCAs were categorized as LR-5. Three tesla MR showed higher sensitivity than 1.5 T in diagnosing HCC (80.00% vs 57.69%, P = 0.015).

CONCLUSION: When the effect of field strength was eliminated, LI-RADS v2018 demonstrated high specificity but suboptimal sensitivity in distinguishing HCC from non-HCC primary liver carcinomas. Most iCCAs were categorized as LR-M or LR-TIV (may be due to non-HCC malignancy). However, nearly half of cHCC-CCAs were assigned as LR-5.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Zou X, Luo Y, Morelli JN, et al. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018. Abdom Radiol (NY). 2021. PMID: 33660040. doi:10.1007/s00261-021-02996-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。